Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD56-Enriched Donor Lymphocyte Infusion · 1 trial · 5 indications
Proportion of patients undergoing BFR-TBI conditioning + haploidentical alloHSCT alive at 30 days post-transplantation.
| Arm | Type | Description |
|---|---|---|
| Subjects | EXPERIMENTAL | Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion |
| Controls | NO_INTERVENTION | Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis. |
| Name | Type | Description |
|---|---|---|
| Total Body Irradiation | RADIATION | Pre-Transplantation Total Body Irradiation |
| Haploidentical Stem Cell Transplantation | PROCEDURE | Haploidentical Stem Cell Transplantation |
| CD56-Enriched Donor Lymphocyte Infusion | BIOLOGICAL | CD56-Enriched Donor Lymphocyte Infusion |
| Bendamustine | DRUG | Pre-Transplantation Bendamustine |
| Fludarabine | DRUG | Pre-Transplantation Fludarabine |
| Rituximab | DRUG | Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only) |
General Inclusion Criteria (For Treatment Groups) * Patient age 18 - 75 years * ECOG 0 - 2 * HIV-positive patients are allowed if these criteria are met: 1. No history of opportunistic infections 2. CD4+ cell count greater or equal to 250 cells/mm3 3. No history of non-malignancy AIDS-defini...
Top 20 of 25 competitors
CD56-Enriched Donor Lymphocyte Infusion is an investigational cell therapy being studied for use in multiple myeloma, as well as other blood cancers such as chronic lymphocytic leukemia, lymphoma, and Hodgkin lymphoma. It is administered as a prophylactic treatment following a haploidentical stem cell transplant.
CD56-Enriched Donor Lymphocyte Infusion is being developed by Teva Pharmaceutical Industries Limited, which trades on the New York Stock Exchange under the ticker TEVA. The company is conducting clinical research on this investigational therapy for oncology indications.
CD56-Enriched Donor Lymphocyte Infusion is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the therapy is not currently in active clinical trials.
CD56-Enriched Donor Lymphocyte Infusion has been studied in one completed clinical trial, identified as NCT03524235. This Phase 1 trial, titled 'Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL,' enrolled 20 participants in the United States.
CD56-Enriched Donor Lymphocyte Infusion is a type of donor lymphocyte infusion enriched for CD56-positive cells, which include natural killer cells. The clinical trial NCT03524235 describes it as a prophylactic natural killer DLI, indicating it is a natural killer cell-based therapy.